This is a working overview of Nuclear receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-27. Anything still debated is marked as such rather than presented as settled.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
== Clinical significance == Mutations in this gene have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of this protein has been seen in many tumors and is also associated with Alzheimer's disease (AD).
Half Wild is young adult fantasy novel, and the second book in the Half-Life trilogy by Sally Green. It was published on 24 March 2015 and is the sequel to Half Bad, which was released the previous year.
In the early 11th century, the Islamic medical philosopher Avicenna wrote extensively on many subjects including medicine. Forty of these treatises on medicine survive, and in the most famous one titled the Canon of Medicine he discusses "rising gas". Avicenna believed that digestive system dysfunction was responsible for the overproduction of gas in the gastrointestinal tract. He suggested lifestyle changes and a compound of herbal drugs for its treatment. In 1497, Alessandro Benedetti viewed the stomach as an unclean organ separated off by the diaphragm. This view of the stomach and intestines as being base organs was generally held until the mid-17th century. In the Renaissance of the 16th century, Leonardo da Vinci produced some early drawings of the stomach and intestines. He thought that the digestive system aided the respiratory system. Andreas Vesalius provided some early anatomical drawings of the abdominal organs in the 16th century. In the middle of the 17th century, a Flemish physician Jan Baptist van Helmont offered the first chemical account of digestion which was later described as being very close to the later conceptualised enzyme. In 1653, William Harvey described the intestines in terms of their length, their blood supply, the mesenteries, and fat (adenylyl cyclase). In 1823, William Prout discovered hydrochloric acid in the gastric juice. In 1895, Ivan Pavlov described its secretion as being stimulated by a neurologic reflex with the vagus nerve having a crucial role. Black in the 19th century suggested an association of histamine with this secretion.
Sources: en.wikipedia.org
The expected structure of the neurotoxin consists of four disulfide bonds, which are arranged in the following manner: 1–4, 2–5, 3–8, 6–7. Three of the disulfide bonds are believed to form an inhibitor cystine knot, which is known to increase resistance to heat denaturation and proteolysis. Transcriptomics has revealed the presence of both an N-terminal signal peptide and a pro peptide, which are cleaved after translation.
Digestible Indispensable Amino Acid Score (DIAAS) is a protein quality method proposed in March 2013 by the Food and Agriculture Organization to replace the current protein ranking standard, the Protein Digestibility Corrected Amino Acid Score (PDCAAS). The DIAAS accounts for amino acid digestibility at the end of the small intestine (= the end of ileum, the last section of the small intestine), providing a more accurate measure of the amounts of amino acids absorbed by the body and the protein's contribution to human amino acid and nitrogen requirements. This is in contrast to the PDCAAS, which is based on an estimate of total protein digestibility over the total digestive tract. Values stated using PDCAAS generally overestimate the amount of amino acids absorbed.
. Special relativity also redefines the concept of mass and energy, which can be used interchangeably and are defined relative to the frame of reference. Several quantities had to be defined for consistency, such as the rest mass of a particle (mass in the rest frame of the particle) and the relativistic mass (in another frame). The latter term is usually less frequently used. In general relativity, conservation of both mass and energy is not globally conserved and its definition is more complicated.
James William Middleton (born 15 April 1987) is a British entrepreneur who is the younger brother of Catherine, Princess of Wales. Born in Reading, Berkshire, Middleton was educated at St Andrew's School, Pangbourne. He briefly attended the University of Edinburgh before dropping out and founding a cake-making business. Middleton began receiving media attention during his eldest sister's relationship with and subsequent marriage to Prince William. He is a mental health advocate and has spoken about his experiences with major depressive disorder. Middleton is also an ambassador for the Pets As Therapy charity.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.